Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer
AR Parikh, EE Van Seventer, G Siravegna… - Clinical Cancer …, 2021 - AACR
Purpose: Detection of persistent circulating tumor DNA (ctDNA) after curative-intent surgery
can identify patients with minimal residual disease (MRD) who will ultimately recur. Most …
can identify patients with minimal residual disease (MRD) who will ultimately recur. Most …
The application of circulating tumor DNA in the screening, surveillance, and treatment monitoring of colorectal cancer
H Xie, RD Kim - Annals of Surgical Oncology, 2021 - Springer
Precision medicine with genetic profiling of tumor tissue has become an essential part of
routine clinical practice in colorectal cancer. However, tissue genetic profiling suffers from …
routine clinical practice in colorectal cancer. However, tissue genetic profiling suffers from …
[HTML][HTML] A serum metabolomics classifier derived from elderly patients with metastatic colorectal cancer predicts relapse in the adjuvant setting
Simple Summary Around 30–40% of patients with early stage colorectal cancer (eCRC)
experience relapse after surgery. Current recommendations for adjuvant therapy are based …
experience relapse after surgery. Current recommendations for adjuvant therapy are based …
[HTML][HTML] Возможности клинического использования внеклеточного ДНК при колоректальном раке
М Тилляшайхов, С Баймаков, А Аширметов… - Медицина и …, 2021 - inlibrary.uz
Колоректальный рак в последние годы считается одним из актуальных проблем
медицины. Учитывая развитие медицинской технологии диагностирование КРР …
медицины. Учитывая развитие медицинской технологии диагностирование КРР …
[HTML][HTML] Colon Cancer, Prognosis After Surgery: What Are the Risks of Recurrent Disease, and How Do We Find Those at Risk?
E Osterman - 2021 - diva-portal.org
Future investigations of the cohort from paper II are planned with immunohistochemistry,
tumour-normal tissue sequencing and biomarkers. In summary, recurrence rates have …
tumour-normal tissue sequencing and biomarkers. In summary, recurrence rates have …
Markers predictive of response, resistance and relapse in colorectal cancer
N Starling - 2021 - repository.icr.ac.uk
Response to neo-adjuvant chemo-radiotherapy (CRT) in locally advanced rectal cancer
varies. Circulating tumour DNA (ctDNA) has emerged as a surrogate marker of the tumour …
varies. Circulating tumour DNA (ctDNA) has emerged as a surrogate marker of the tumour …